Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer
Summary
The purpose of this phase II trial is to learn if a person's white blood cells modified with T-cell receptors can cause solid tumors to shrink.
General Information
NCT#: NCT04102436
Study ID: 190143
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Cyclophosphamide, Aldesleukin, Fludarabine, Sleeping Beauty Transposed PBL